Tech Company Financing Transactions

Lutris Pharma Funding Round

Lutris Pharma, based in Tel Aviv, received $30 million from Columbus Venture Partners, Pontifax Venture Capital and aMoon Fund.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

27 Habarzel Street
Tel Aviv, Undisclosed
Israel

Phone

Undisclosed

Website

www.lutris-pharma.com

Email Address

[email protected]

Overview

Lutris Pharma is a clinical stage biopharmaceutical company established with a vision to improve anti cancer therapy effectiveness as well as the quality of life for patients who are being treated with EGFR (Epidermal Growth Factor Receptor) Inhibitors or with Radiation.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Noa Shelach

        

Chief Medical Officer

Ben Corn

        

VP - Bus. Development

Colleen Johnson

        

VP - Manufacturing

Laura Millichamp

        

VP - Regulatory Affairs

John Waymack

        

Browse more venture capital transactions:

Prev: 1/28/2025: Amplitude Vascular Systems venture capital transaction
Next: 1/28/2025: Adsorbi venture capital transaction

Share this article

About Our Venture Capital Transactions Database

Our team works diligently to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary